688382 益方生物-U
交易中 11-10 13:29:04
资讯
新帖
简况
益方生物（688382）11月6日主力资金净买入71.44万元
证券之星 · 11-07
益方生物（688382）11月6日主力资金净买入71.44万元
毛利率“变脸王”频出，谁在真赚钱？拆解2026年三季报中“真拐点与假繁荣”
东方财富网 · 11-05
毛利率“变脸王”频出，谁在真赚钱？拆解2026年三季报中“真拐点与假繁荣”
益方生物（688382）11月2日主力资金净买入4133.21万元
证券之星 · 11-03
益方生物（688382）11月2日主力资金净买入4133.21万元
益方生物：银屑病新药III期临床达主要终点
证券之星 · 11-01
益方生物：银屑病新药III期临床达主要终点
益方生物(688382)9月30日股东户数1.46万户，较上期减少1.37%
证券之星 · 10-30
益方生物(688382)9月30日股东户数1.46万户，较上期减少1.37%
益方生物（688382）披露2026年第三季度报告，10月29日股价下跌3.46%
证券之星 · 10-29
益方生物（688382）披露2026年第三季度报告，10月29日股价下跌3.46%
益方生物（688382）10月26日主力资金净卖出1122.74万元
证券之星 · 10-27
益方生物（688382）10月26日主力资金净卖出1122.74万元
益方生物（688382）10月22日主力资金净卖出1444.61万元
证券之星 · 10-23
益方生物（688382）10月22日主力资金净卖出1444.61万元
益方生物（688382）10月15日主力资金净买入553.45万元
证券之星 · 10-16
益方生物（688382）10月15日主力资金净买入553.45万元
益方生物（688382）10月13日主力资金净买入340.88万元
证券之星 · 10-14
益方生物（688382）10月13日主力资金净买入340.88万元
益方生物（688382）10月8日主力资金净买入685.89万元
证券之星 · 10-09
益方生物（688382）10月8日主力资金净买入685.89万元
益方生物科技（688382）9月28日主力资金净买入246.74万元
证券之星 · 09-29
益方生物科技（688382）9月28日主力资金净买入246.74万元
翰森制药TYK2新药III期告捷，直面进口、国产、生物制剂三面挤压：商业化突围挑战重重，第二增长曲线仍待验证
同花顺 · 09-23
翰森制药TYK2新药III期告捷，直面进口、国产、生物制剂三面挤压：商业化突围挑战重重，第二增长曲线仍待验证
每周股票复盘：益方生物（688382）重新递表港交所拟发行H股
证券之星 · 08-30
每周股票复盘：益方生物（688382）重新递表港交所拟发行H股
益方生物（688382）披露召开2026年半年度业绩说明会公告，8月25日股价上涨0.52%
证券之星 · 08-25
益方生物（688382）披露召开2026年半年度业绩说明会公告，8月25日股价上涨0.52%
益方生物：重新递交H股发行上市申请
证券之星 · 08-23
益方生物：重新递交H股发行上市申请
每周股票复盘：益方生物（688382）股东户数减少16.7%
证券之星 · 08-23
每周股票复盘：益方生物（688382）股东户数减少16.7%
默沙东研发中国签署合作协议，携手益方生物推进小分子肿瘤药物临床开发
美股速递 · 08-11
默沙东研发中国签署合作协议，携手益方生物推进小分子肿瘤药物临床开发
默沙东与益方生物签署合作协议 推进肿瘤领域小分子药物临床开发
智通财经 · 08-11
默沙东与益方生物签署合作协议 推进肿瘤领域小分子药物临床开发
股市必读：益方生物（688382）8月4日董秘有最新回复
证券之星 · 08-05
股市必读：益方生物（688382）8月4日董秘有最新回复
加载更多
公司概况
公司名称：
益方生物科技(上海)股份有限公司
所属行业：
医药制造业
上市日期：
2022-07-25
主营业务：
益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是贝福替尼、格索雷塞。
发行价格：
18.12
{"stockData":{"symbol":"688382","market":"SH","secType":"STK","nameCN":"益方生物-U","latestPrice":13.95,"timestamp":1794288544000,"preClose":13.62,"halted":0,"volume":10133451,"delay":0,"changeRate":0.0242,"floatShares":580000000,"shares":580000000,"eps":-0.6544,"marketStatus":"交易中","change":0.33,"latestTime":"11-10 13:29:04","open":13.82,"high":14.11,"low":13.61,"amount":140000000,"amplitude":0.0367,"askPrice":13.95,"askSize":20,"bidPrice":13.92,"bidSize":229,"shortable":0,"etf":0,"ttmEps":-0.6544,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1794294000000},"marketStatusCode":2,"adr":0,"adjPreClose":13.62,"symbolType":"stock_kcb","openAndCloseTimeList":[[1794274200000,1794281400000],[1794286800000,1794294000000]],"highLimit":14.98,"lowLimit":12.26,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":579608522,"isCdr":false,"pbRate":6,"roa":"--","roe":"--","epsLYR":-0.5479,"committee":0.160458,"marketValue":8086000000,"turnoverRate":0.0175,"status":0,"floatMarketCap":8086000000},"requestUrl":"/m/hq/s/688382","defaultTab":"news","newsList":[{"id":"2681813358","title":"益方生物（688382）11月6日主力资金净买入71.44万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681813358","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681813358?lang=zh_cn&edition=full","pubTime":"2026-11-07 09:23","pubTimestamp":1794014591,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月6日收盘，益方生物报收于13.68元，下跌5.33%，换手率3.95%，成交量22.91万手，成交额3.2亿元。近5日资金流向一览见下表：益方生物融资融券信息显示，融资方面，当日融资买入1974.35万元，融资偿还2732.64万元，融资净偿还758.29万元。益方生物主营业务：致力于研制出具有自主知识产权、中国创造并面向全球的创新药物,持之以恒地为患者提供更加安全、有效、可负担的治疗方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110700010225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681406780","title":"毛利率“变脸王”频出，谁在真赚钱？拆解2026年三季报中“真拐点与假繁荣”","url":"https://stock-news.laohu8.com/highlight/detail?id=2681406780","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681406780?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:33","pubTimestamp":1793871197,"startTime":"0","endTime":"0","summary":"一边是毛利率高达99%的“躺赚”神话，一边却是-512%的“做一单亏一单”深渊。2026年三季报即将落下帷幕，财报数据呈现出了极致的“冰火两重天”。在这个财报季，到底该如何撕开数据表象，发现哪些公司的改善是“真拐点”，哪些只是“账面修复”，又有哪些是数字“幻觉”？答案，藏在两组关键数据的交叉验证之中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1354,202611053923597196.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202611053923597196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["BK0196","002059","UBmain","BK0271","688303","BK0109","BK0059","300197","BK0235","BK0146","BK0251","BK0101","BK0239","ZFmain","BK0145","BK0267","688197","BK0276","300093","BK0241","BK0077","002432","ZBmain","600996","688192","BK0012","BK0218","BK0201","ZTmain","BK0188","BK0183","BK0178","BK0094","BK0102","002343","688382","688765","BK0028","600783","BK0087","BK0075","688670","600674","BK0114","BK0261","ZNmain","TNmain","688302","BK0224","300357"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680503792","title":"益方生物（688382）11月2日主力资金净买入4133.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680503792","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680503792?lang=zh_cn&edition=full","pubTime":"2026-11-03 08:25","pubTimestamp":1793665557,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月2日收盘，益方生物报收于13.17元，上涨6.3%，换手率8.43%，成交量48.85万手，成交额6.26亿元。近5日资金流向一览见下表：益方生物融资融券信息显示，融资方面，当日融资买入3206.46万元，融资偿还1753.72万元，融资净买入1452.74万元，连续3日净买入累计1814.44万元。益方生物主营业务：致力于研制出具有自主知识产权、中国创造并面向全球的创新药物,持之以恒地为患者提供更加安全、有效、可负担的治疗方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300010344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680205437","title":"益方生物：银屑病新药III期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2680205437","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680205437?lang=zh_cn&edition=full","pubTime":"2026-11-01 15:49","pubTimestamp":1793519397,"startTime":"0","endTime":"0","summary":"益方生物(688382.SH)公告称，公司自主研发的靶向TYK2JH2新型口服选择性抑制剂nomelcitinib(D-2570)治疗中重度斑块状银屑病注册性III期临床研究达到主要终点和关键次要终点。研究共纳入391例患者，治疗第16周时两个治疗组PASI90患者比例均达70%以上，PGA0/1患者比例均达80%以上，显著高于安慰剂组。药物安全性良好，未发现新安全性信号。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110100003712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679218091","title":"益方生物(688382)9月30日股东户数1.46万户，较上期减少1.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679218091","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679218091?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:12","pubTimestamp":1793358774,"startTime":"0","endTime":"0","summary":"证券之星消息，近日益方生物披露，截至2026年9月30日公司股东户数为1.46万户，较6月30日减少202.0户，减幅为1.37%。在化学制药行业个股中，益方生物股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.98万户。从股价来看，2026年6月30日至2026年9月30日，益方生物区间涨幅为5.94%，在此期间股东户数减少202.0户，减幅为1.37%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000046700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679728573","title":"益方生物（688382）披露2026年第三季度报告，10月29日股价下跌3.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679728573","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679728573?lang=zh_cn&edition=full","pubTime":"2026-10-29 22:07","pubTimestamp":1793282820,"startTime":"0","endTime":"0","summary":"截至2026年10月29日收盘，益方生物报收于13.12元，较前一交易日下跌3.46%，最新总市值为76.04亿元。近日，益方生物披露《2026年第三季度报告》。报告显示，本报告期营业收入为11,341,381.59元，较上年同期下降3.31%；年初至报告期末营业收入为64,660,538.85元，同比增长109.30%。本报告期研发投入合计110,323,764.13元，同比增长48.70%；年初至报告期末研发投入合计295,039,960.84元，同比增长55.57%。本报告期末总资产为1,427,291,866.32元，较上年度末下降16.23%；归属于上市公司股东的所有者权益为1,314,753,838.88元，较上年度末下降14.41%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900062722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678214816","title":"益方生物（688382）10月26日主力资金净卖出1122.74万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678214816","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678214816?lang=zh_cn&edition=full","pubTime":"2026-10-27 08:32","pubTimestamp":1793061161,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月26日收盘，益方生物报收于14.48元，下跌4.3%，换手率2.2%，成交量12.74万手，成交额1.87亿元。近5日资金流向一览见下表：益方生物融资融券信息显示，融资方面，当日融资买入877.48万元，融资偿还524.57万元，融资净买入352.91万元。益方生物主营业务：致力于研制出具有自主知识产权、中国创造并面向全球的创新药物,持之以恒地为患者提供更加安全、有效、可负担的治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700010492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677918783","title":"益方生物（688382）10月22日主力资金净卖出1444.61万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677918783","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677918783?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:26","pubTimestamp":1792715208,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月22日收盘，益方生物报收于14.38元，下跌7.05%，换手率2.32%，成交量13.47万手，成交额2.0亿元。近5日资金流向一览见下表：益方生物融资融券信息显示，融资方面，当日融资买入967.81万元，融资偿还714.88万元，融资净买入252.94万元。益方生物主营业务：致力于研制出具有自主知识产权、中国创造并面向全球的创新药物,持之以恒地为患者提供更加安全、有效、可负担的治疗方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300007591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675928559","title":"益方生物（688382）10月15日主力资金净买入553.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675928559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675928559?lang=zh_cn&edition=full","pubTime":"2026-10-16 08:22","pubTimestamp":1792110141,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月15日收盘，益方生物报收于15.51元，下跌0.58%，换手率1.89%，成交量10.94万手，成交额1.74亿元。近5日资金流向一览见下表：益方生物融资融券信息显示，融资方面，当日融资买入578.04万元，融资偿还823.71万元，融资净偿还245.67万元。益方生物主营业务：致力于研制出具有自主知识产权、中国创造并面向全球的创新药物,持之以恒地为患者提供更加安全、有效、可负担的治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600007273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675239681","title":"益方生物（688382）10月13日主力资金净买入340.88万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675239681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675239681?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:29","pubTimestamp":1791937742,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，益方生物报收于16.19元，下跌2.47%，换手率1.83%，成交量10.58万手，成交额1.69亿元。近5日资金流向一览见下表：益方生物融资融券信息显示，融资方面，当日融资买入407.68万元，融资偿还712.95万元，融资净偿还305.26万元。益方生物主营业务：致力于研制出具有自主知识产权、中国创造并面向全球的创新药物,持之以恒地为患者提供更加安全、有效、可负担的治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400007250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674524889","title":"益方生物（688382）10月8日主力资金净买入685.89万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674524889","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674524889?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:26","pubTimestamp":1791505598,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，益方生物报收于17.33元，下跌9.12%，换手率3.47%，成交量20.11万手，成交额3.59亿元。近5日资金流向一览见下表：益方生物融资融券信息显示，融资方面，当日融资买入1566.93万元，融资偿还1025.82万元，融资净买入541.11万元。益方生物主营业务：致力于研制出具有自主知识产权、中国创造并面向全球的创新药物,持之以恒地为患者提供更加安全、有效、可负担的治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900006090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671269689","title":"益方生物科技（688382）9月28日主力资金净买入246.74万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671269689","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671269689?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:38","pubTimestamp":1790642312,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月28日收盘，益方生物科技报收于17.65元，下跌5.87%，换手率2.79%，成交量16.16万手，成交额2.88亿元。近5日资金流向一览见下表：益方生物科技融资融券信息显示，融资方面，当日融资买入1851.88万元，融资偿还807.14万元，融资净买入1044.74万元，连续3日净买入累计1897.76万元。益方生物科技主营业务：致力于研制出具有自主知识产权、中国创造并面向全球的创新药物,持之以恒地为患者提供更加安全、有效、可负担的治疗方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900007455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["HBImain","159837","BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669173759","title":"翰森制药TYK2新药III期告捷，直面进口、国产、生物制剂三面挤压：商业化突围挑战重重，第二增长曲线仍待验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2669173759","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669173759?lang=zh_cn&edition=full","pubTime":"2026-09-23 08:13","pubTimestamp":1790122380,"startTime":"0","endTime":"0","summary":"翰森制药（03692.HK）旗下口服TYK2抑制剂在III期临床中达到主要终点，标志着其在自身免疫疾病领域迎来重要里程碑。9月21日，翰森制药公告称，自研酪氨酸激酶2（TYK2）选择性变构抑制剂HS-10 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260923/c680191975.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260923/c680191975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688336","BK0239","688428","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663045972","title":"每周股票复盘：益方生物（688382）重新递表港交所拟发行H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2663045972","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663045972?lang=zh_cn&edition=full","pubTime":"2026-08-30 10:04","pubTimestamp":1788055453,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，益方生物报收于20.09元，较上周的20.0元上涨0.45%。本周关注点公司公告汇总：益方生物重新向港交所递交H股上市申请。公司公告汇总益方生物关于重新向香港联合交易所有限公司递交H股发行上市申请并刊发申请资料的公告益方生物科技（上海）股份有限公司于2026年8月21日重新向香港联合交易所有限公司递交发行H股股票并在香港联交所主板上市的申请，并于同日在香港联交所网站刊发了申请资料。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000004773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["HEXmain","BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662758915","title":"益方生物（688382）披露召开2026年半年度业绩说明会公告，8月25日股价上涨0.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662758915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662758915?lang=zh_cn&edition=full","pubTime":"2026-08-25 22:11","pubTimestamp":1787667118,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，益方生物报收于19.16元，较前一交易日上涨0.52%，最新总市值为111.05亿元。该股当日开盘19.08元，最高19.45元，最低18.23元，成交额达2.93亿元，换手率为2.67%。公告显示，公司将于2026年9月2日10:00-11:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会，介绍公司经营成果及财务状况。投资者可于2026年8月26日至9月1日16:00前通过上证路演中心网站或公司邮箱ir@inventisbio.com提问，公司将在说明会上对普遍关注的问题进行回应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500050340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661669210","title":"益方生物：重新递交H股发行上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2661669210","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661669210?lang=zh_cn&edition=full","pubTime":"2026-08-23 15:40","pubTimestamp":1787470810,"startTime":"0","endTime":"0","summary":"益方生物(688382.SH)公告称，公司于8月21日重新向香港联交所递交H股发行上市申请，并于同日在香港联交所网站刊登申请资料。该申请材料为草拟版本，投资者不应据此作出投资决定。本次发行上市尚需取得证监会、香港证监会及香港联交所等批准，存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300004171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661214835","title":"每周股票复盘：益方生物（688382）股东户数减少16.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661214835","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661214835?lang=zh_cn&edition=full","pubTime":"2026-08-23 03:03","pubTimestamp":1787425389,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，益方生物报收于20.0元，较上周的21.09元下跌5.17%。本周，益方生物8月18日盘中最高价报22.64元。股本股东变化股东户数变动截至2026年6月30日，益方生物股东户数为1.48万户，较3月31日减少2960户，减幅为16.7%。本次符合归属条件的激励对象为2名，归属股票数量为1.6518万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110770273","title":"默沙东研发中国签署合作协议，携手益方生物推进小分子肿瘤药物临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1110770273","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110770273?lang=zh_cn&edition=full","pubTime":"2026-08-11 15:39","pubTimestamp":1786433970,"startTime":"0","endTime":"0","summary":"默沙东研发中国（Msd R&D China）宣布，已与益方生物（Inventisbio）正式签署一项合作协议。此次合作旨在共同推进小分子肿瘤药物的临床开发进程。公司在一份声明中披露了该消息，双方将集中资源，致力于加速相关候选药物的研究、试验与申报工作，以期早日为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN8TJ469.HKD","LU1923622614.USD","LU2361045086.USD","IE00BJJMRZ35.SGD","BK4534","LU1023059063.AUD","LU1066051225.USD","TRUH","LU1929549753.HKD","LU0965509010.AUD","LU0289739699.SGD","LU1291159041.SGD","IE0009355771.USD","LU2461242641.AUD","LU1093756168.USD","BK4007","LU0432979614.USD","SG9999014575.USD","LU1066053197.SGD","LU0070302665.USD","LU0122379950.USD","LU1057294990.SGD","LU1934455277.USD","LU2433249047.HKD","SG9999015341.SGD","JDOC","BK0239","IE00B1BXHZ80.USD","LU0689626769.HKD","SG9999014542.SGD","LU2491049909.HKD","LU1037948541.HKD","SGXZ57979304.SGD","LU1934455194.USD","LU2089984988.USD","LU1585245621.USD","LU0266013472.USD","IXJ","SG9999001440.SGD","VHT","IE0002141913.USD","LU0124676726.USD","BK4559","LU1917777945.USD","LU0203347892.USD","LU1093756325.SGD","LU1066051498.USD","LU1571399168.USD","SG9999001176.SGD","IE00BLSP4452.SGD","LU2125154935.USD","IHE","LU2491050071.SGD","IE00B4R5TH58.HKD","LU0130517989.USD","LU1989771016.USD","IE00BSNM7G36.USD","LU0106261372.USD","LU2324357040.USD","LU0234572021.USD","LU0985320562.USD","LU0868494708.USD","LU2360032135.SGD","LU0058720904.USD","LU0823416689.USD","LU0098860793.USD","SG9999014567.USD","XLV","LU0648001328.SGD","LU1201861249.SGD","LU2361044949.HKD","IYH","LU0006306889.USD","LU1983299246.USD","LU2491050154.USD","LU0942090050.USD","LU0208291251.USD","LU0980610538.SGD","BK4516","IE00BBT3K403.USD","RXL","LU1974910355.USD","LU1116320737.USD","LU0477156953.USD","IE00BJT1NW94.SGD","LU0265550359.USD","LU0965508806.USD","GDOC","PAWZ","SG9999013999.USD","PPH","SG9999001176.USD","LU0203345920.USD","MRK","BK4533","LU0320765489.SGD","FHLC","LU1430594728.SGD","LU1162221912.USD","LU1066051811.HKD","HRTS","LU0965509283.SGD","LU1699723380.USD","LU1037948897.HKD","SG9999015358.SGD","LU1116320901.HKD","LU2112291526.USD","LU1941712348.USD","LU2106854487.HKD","LU2357627491.SGD","LU0211331839.USD","LU2023250843.SGD","LU1069347547.HKD","FTXH","LU2125154778.USD","IE000M9KFDE8.USD","SG9999002224.SGD","IE00BFTCPJ56.SGD","LU1934455863.HKD","LU0859254822.USD","LU1941712264.USD","LU0320765646.SGD","LU2125909593.SGD","IE00BLSP4239.USD","BMED","BK4585","LU2023250504.SGD","LU0868494617.USD","LU1989772923.USD","LU1061106388.HKD","LU0130102774.USD","SG9999002232.USD","LU0861579265.USD","LU0238689110.USD","LU2361044865.SGD","LU0265550946.USD","BK4588","LU2125909247.SGD","IE00B2B36J28.USD","SG9999014559.SGD","LU1989772840.SGD","LU0965509101.SGD","688382","LU2468319806.SGD","LU1035773651.USD","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658734960","title":"默沙东与益方生物签署合作协议 推进肿瘤领域小分子药物临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658734960","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658734960?lang=zh_cn&edition=full","pubTime":"2026-08-11 15:35","pubTimestamp":1786433748,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0477156953.USD","IE00BN8TJ469.HKD","SG9999015358.SGD","LU0859254822.USD","LU1934455194.USD","TRUH","LU1093756325.SGD","LU0289739699.SGD","LU0985320562.USD","IE0009355771.USD","LU2023250843.SGD","LU2112291526.USD","LU0122379950.USD","BK4516","GDOC","SG9999014542.SGD","IE00BLSP4452.SGD","LU2023250504.SGD","LU1934455863.HKD","PAWZ","LU0965509010.AUD","FTXH","IE00BBT3K403.USD","LU2361044865.SGD","LU1571399168.USD","LU0203345920.USD","LU2125909247.SGD","LU0203347892.USD","LU0265550946.USD","LU1923622614.USD","IE0002141913.USD","LU0070302665.USD","LU1066051498.USD","LU0965508806.USD","LU1934455277.USD","LU0265550359.USD","LU0124676726.USD","LU1699723380.USD","LU2491050154.USD","LU0098860793.USD","LU2360032135.SGD","LU0823416689.USD","LU2468319806.SGD","LU1162221912.USD","LU0238689110.USD","LU0648001328.SGD","LU1291159041.SGD","IE00B4R5TH58.HKD","LU1941712348.USD","LU1057294990.SGD","LU1066053197.SGD","LU1430594728.SGD","BK4585","LU1037948541.HKD","JDOC","LU1929549753.HKD","LU1116320901.HKD","LU2491050071.SGD","LU1917777945.USD","LU0965509283.SGD","LU1066051811.HKD","LU2357627491.SGD","LU0320765489.SGD","IE00BJT1NW94.SGD","IE00B1BXHZ80.USD","LU0234572021.USD","IE00B2B36J28.USD","SG9999014559.SGD","LU1037948897.HKD","HRTS","LU2491049909.HKD","IE00BFTCPJ56.SGD","IHE","LU2106854487.HKD","LU1093756168.USD","LU2125154935.USD","XLV","LU0861579265.USD","LU0130517989.USD","BK4588","LU2461242641.AUD","SG9999001176.USD","SG9999013999.USD","LU0868494617.USD","LU1989772840.SGD","BK0239","LU0006306889.USD","IXJ","LU1983299246.USD","IE00BSNM7G36.USD","BMED","LU0689626769.HKD","LU2125154778.USD","LU2361044949.HKD","BK4534","LU2089984988.USD","LU2433249047.HKD","RXL","SG9999001440.SGD","LU1023059063.AUD","FHLC","LU1035773651.USD","LU1989772923.USD","IE000M9KFDE8.USD","LU1585245621.USD","LU1069347547.HKD","LU2324357040.USD","PPH","IYH","MRK","LU0942090050.USD","SGXZ57979304.SGD","SG9999014567.USD","LU2125909593.SGD","LU1201861249.SGD","LU0211331839.USD","LU1974910355.USD","LU2361045086.USD","LU0432979614.USD","BK4559","LU0130102774.USD","LU0208291251.USD","LU0266013472.USD","LU1116320737.USD","SG9999015341.SGD","LU0868494708.USD","BK4007","BK4550","LU1989771016.USD","SG9999002224.SGD","688382","LU1061106388.HKD","LU0965509101.SGD","BK4533","SG9999001176.SGD","SG9999014575.USD","LU0058720904.USD","VHT","IE00BJJMRZ35.SGD","LU0980610538.SGD","IE00BLSP4239.USD","LU1941712264.USD","LU0106261372.USD","LU1066051225.USD","LU0320765646.SGD","SG9999002232.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657563853","title":"股市必读：益方生物（688382）8月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2657563853","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657563853?lang=zh_cn&edition=full","pubTime":"2026-08-05 01:30","pubTimestamp":1785864632,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，益方生物报收于18.69元，下跌0.53%，换手率4.93%，成交量28.6万手，成交额5.38亿元。希望2026年年报细化人力资本投入、员工发展通道及核心人才留存的披露，并说明公司计划通过哪些机制提升人均产出、增强骨干员工稳定性。感谢您对公司人才建设及长期可持续发展的关注。当日关注点交易信息汇总：8月4日主力资金净流出790.89万元，游资资金净流出2499.24万元，散户资金净流入3290.13万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500001662.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794288549271,"stockEarnings":[{"period":"1week","weight":0.0342},{"period":"1month","weight":-0.2109},{"period":"3month","weight":-0.3502},{"period":"6month","weight":-0.3995},{"period":"1year","weight":-0.4535},{"period":"ytd","weight":-0.5}],"compareEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":-0.0401},{"period":"3month","weight":-0.0695},{"period":"6month","weight":-0.1371},{"period":"1year","weight":-0.0842},{"period":"ytd","weight":-0.0776}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"益方生物科技(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14564人(较上一季度减少1.37%)","perCapita":"39797股","listingDate":"2022-07-25","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路67弄4号210室","registeredCapital":"57960万元","survey":" 益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是贝福替尼、格索雷塞。","listedPrice":18.12},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"益方生物-U(688382)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供益方生物-U(688382)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"益方生物-U,688382,益方生物-U股票,益方生物-U股票老虎,益方生物-U股票老虎国际,益方生物-U行情,益方生物-U股票行情,益方生物-U股价,益方生物-U股市,益方生物-U股票价格,益方生物-U股票交易,益方生物-U股票购买,益方生物-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"益方生物-U(688382)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供益方生物-U(688382)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}